|
|
- 2018
Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's diseaseDOI: 10.1016/j.trci.2018.03.004 Keywords: MK-7622, Alzheimer's disease, Cholinergic, Muscarinic, Allosteric modulator, Clinical trial Abstract: We evaluated the selective M1 muscarinic positive allosteric modulator, MK-7622, as adjunctive cognitive enhancing therapy in individuals with Alzheimer's disease
|
